Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1999-9-9
pubmed:abstractText
We have compared the membrane transport and antitumor activity of pirarubicin with those of doxorubicin in M5076 ovarian sarcoma, which exhibits low sensitivity to doxorubicin. Pirarubicin was rapidly taken up by M5076 cells and the intracellular concentration of pirarubicin reached more than 2.5-fold that of doxorubicin. In terms of the 50% cell growth-inhibitory concentration in vitro, pirarubicin was more effective than doxorubicin. Thus, the intracellular concentration influenced the cytotoxicity of these anthracycline agents. On comparison of the nuclear uptake of pirarubicin and doxorubicin, the nucleus/cell ratio of pirarubicin was found to be about 40%, whereas that of doxorubicin reached more than 80%. As the intranuclear concentration of pirarubicin is dependent on nuclear transport, the increases in not only cell membrane transport, but also nuclear membrane transport contributed to the enhancement of the efficacy of pirarubicin. In M5076 solid tumor-bearing mice, pirarubicin reduced the tumor weight to 60% of the control level, although doxorubicin had no effect. These results were supported by the intracellular uptake of pirarubicin. Moreover, theanine, which inhibited the pirarubicin efflux from M5076 cells, increased by 1.3-fold the pirarubicin concentration in the tumor and enhanced the therapeutic efficacy of pirarubicin 1.7-fold. In conclusion, our results suggest that an increase in the concentration of an anthracycline derivative in tumor cells due to alteration of cell membrane transport results in enhancement of the antitumor activity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0910-5050
pubmed:author
pubmed:issnType
Print
pubmed:volume
90
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
775-80
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:10470291-Animals, pubmed-meshheading:10470291-Antibiotics, Antineoplastic, pubmed-meshheading:10470291-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:10470291-Biological Transport, pubmed-meshheading:10470291-Cell Division, pubmed-meshheading:10470291-Cell Membrane, pubmed-meshheading:10470291-Cell Nucleus, pubmed-meshheading:10470291-Doxorubicin, pubmed-meshheading:10470291-Drug Interactions, pubmed-meshheading:10470291-Female, pubmed-meshheading:10470291-Glutamates, pubmed-meshheading:10470291-Male, pubmed-meshheading:10470291-Mice, pubmed-meshheading:10470291-Neoplasm Transplantation, pubmed-meshheading:10470291-Ovarian Neoplasms, pubmed-meshheading:10470291-Sarcoma, Experimental, pubmed-meshheading:10470291-Tea, pubmed-meshheading:10470291-Tumor Cells, Cultured
pubmed:year
1999
pubmed:articleTitle
Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin.
pubmed:affiliation
Department of Pharmaceutical Engineering, School of Pharmaceutical Sciences, University of Shizuoka.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't